---
title: Opioid-Free Intraoperative Anesthesia (OFIA) With ACB + IPACK
version: 1.3
last-updated: 2025-12-08
---

# Opioid-Free Intraoperative Anesthesia (OFIA) With ACB + IPACK  
**Protocol 1 – Preferred First-Line rTKA Pathway**

---

## 1. Purpose
Provide a standardized **first-line** opioid-free intraoperative anesthesia (OFIA) pathway for robot-assisted total knee arthroplasty (rTKA) using **adductor canal block (ACB)** and **IPACK**. This protocol optimizes analgesia, minimizes opioid exposure, reduces PONV, preserves quadriceps strength, and supports ERAS goals including **POD 0 ambulation**.

Protocols are **informed by** ERAS 2024, ASA/APSF 2024, and ASRA 2024–2025 but **do not replace** institutional policies or attending anesthesiologist judgment.

> **Educational Use Only – Not a Clinical Guideline**  
> - All doses represent **typical adult ranges** and must be individualized.  
> - Pathway selection remains **attending-dependent**.  
> - Frail, elderly, OSA, cardiac, or renal/hepatic-impaired patients require tailored dosing.

---

## 2. Preoperative Phase

### 2.1 Patient Assessment
- Standard preanesthetic evaluation  
- Review prior anesthesia records  
- Identify risk factors for PONV, delirium, OSA, frailty  
- Opioid tolerance assessment  
- **Confirm suitability for peripheral nerve blocks**  
- ASRA 2024–2025 anticoagulation compliance:
  - **DOACs:** ≥72h if CrCl >50 mL/min (longer if impaired)  
  - **Warfarin:** INR ≤1.4  
  - **Prophylactic LMWH:** ≥12h  
  - **Therapeutic LMWH:** ≥24h  
  - **Aspirin/NSAIDs:** No hold required per ASRA  
  - **Clopidogrel:** Usually acceptable for superficial blocks; follow local policy  

### 2.2 Preoperative Medications (ERAS-Informed)
- **Acetaminophen 1 g PO** (30–60 min pre-op)  
- **Celecoxib 400 mg PO** (1–2 hours pre-op; meloxicam 15 mg alternative)  
- **Dexamethasone 8–10 mg IV** after IV placement  
- **Scopolamine patch 1.5 mg** for *high PONV risk only*  
- **Avoid gabapentinoids** (ASA/APSF 2024 safety advisory)  
- *Midazolam is reserved for block placement anxiolysis (below).*

---

## 3. Regional Blocks (Ultrasound-Guided – Essential for Protocol 1)

### 3.1 Pre-Block Anxiolysis
- **Midazolam 1–2 mg IV**  
  - Use **0.5–1 mg** in elderly/OSA/frail  
  - Avoid oversedation prior to induction

### 3.2 Adductor Canal Block (ACB)
- **20–30 mL ropivacaine 0.2–0.25%** (commonly 25 mL)  
- Subsartorial approach targeting the vastoadductor canal  
- Incremental injection, negative aspiration, visual spread confirmed  

### 3.3 IPACK Block
- **~20 mL ropivacaine 0.2–0.25%**  
- Ultrasound-guided between posterior capsule and popliteal artery  
- Avoid intravascular or intraneural injection; incremental dosing  

### 3.4 Documentation
- Total ropivacaine dose (e.g., 112–125 mg)  
- Maximum safe dose: **~3 mg/kg**  
- Block type, laterality, volume, concentration, patient tolerance  
- Block quality (excellent/good/fair/poor)  
- Confirmation that quadriceps strength is preserved  

### 3.5 Safety
- **Lipid emulsion 20% immediately available**  
- Maintain standard LAST precautions  

---

## 4. Induction

> Doses apply to typical adults; reduce for frail, elderly, or hemodynamically unstable.

### Induction Sequence
- **Midazolam 0.5–1 mg IV** (after earlier block dosing)  
- **Propofol 1.5–2 mg/kg IV**  
- **Ketamine 0.3–0.5 mg/kg IV** (lower end for elderly/cardiac)  
- **Rocuronium 0.6–1.0 mg/kg IV**  

### Optional Adjunct Loading
- **Dexmedetomidine 0.5 mcg/kg over 10–20 minutes**  
- **Magnesium sulfate 30–50 mg/kg** (avoid if CrCl <30 mL/min)

### Airway Management
- ETT vs LMA based on risk profile and surgical factors  
- Confirm placement with ETCO₂  
- Document Cormack–Lehane grade  

---

## 5. Maintenance

### 5.1 Primary Maintenance
- **Sevoflurane ~0.8–1.2 MAC**  
  **OR**  
- **Propofol TIVA 75–150 mcg/kg/min** (for high PONV or MH risk)

### 5.2 Adjuncts
- **Dexmedetomidine 0.2–0.7 mcg/kg/hr**  
  - Use **0.2–0.4** for elderly/frail  
- **Ketamine 0.1–0.25 mg/kg/hr**  

### 5.3 Hemodynamic Management
- Target **MAP ≥65 mmHg**  
- Treat hypotension:
  - **Phenylephrine 50–100 mcg IV** (HR >70)  
  - **Ephedrine 5–10 mg IV** (HR <60)  
- Dex-related bradycardia:
  - **Glycopyrrolate 0.2–0.4 mg IV** (preferred over atropine)

### 5.4 Monitoring
- Standard ASA monitors  
- Agent analyzer for volatile  
- TOF neuromuscular monitoring  
- BIS/depth monitoring (consider strongly for elderly)  

### Key Principle
**Zero intraoperative opioids.**

---

## 6. Emergence

### 6.1 10–15 Minutes Before End
- Stop dexmedetomidine  
- Continue ketamine until closure  

### 6.2 At Skin Closure
- Stop ketamine infusion  
- Taper volatile to **0.5–0.7 MAC** or reduce propofol by ~50%  

### 6.3 Reversal + PONV Prophylaxis
- **Ondansetron 4 mg IV**  
- **Sugammadex 2 mg/kg** (TOF ≥2 but <0.9)  
- **Sugammadex 4 mg/kg** for deep block  

### 6.4 Extubation Criteria
- Awake, follows commands  
- RR 10–20, TV >5 mL/kg  
- SpO₂ >92%  
- TOF ratio ≥0.9  
- Hemodynamically stable  

### 6.5 Expected
- Smooth, controlled emergence  
- Minimal coughing/bucking  
- Typically awake in **10–15 minutes**  
- Low PONV incidence  

---

## 7. Postoperative Phase

### 7.1 Expected Pain Profile
- **NRS 0–3** for first 12–18 hours  
- If NRS ≥4:
  - Evaluate block quality  
  - Consider tourniquet pain  
  - Rule out surgical complication  

### 7.2 Scheduled Multimodal Analgesia
- **Acetaminophen 1 g PO/IV q6h** (max 4 g/day)  
- NSAID options:
  - Celecoxib 200 mg PO q12h  
  - OR Ketorolac 15 mg IV q6h  
  - OR Meloxicam 15 mg PO daily  

### 7.3 Rescue Analgesia (Stepwise)
1. **Ketamine 0.1–0.15 mg/kg IV q10–15 min**  
   - Max ~3 doses  
2. **Hydromorphone 0.2 mg IV**  
   - Only if ketamine inadequate  
   - Enhanced monitoring required  

### 7.4 Mobilization
- POD 0 ambulation typically within **4–6 hours**  
- Quad-sparing block enables safe mobilization  

### 7.5 Block Duration + Transition
- ACB + IPACK duration: **12–18 hours**  
- Ensure robust oral analgesic regimen before block wear-off  
- Anticipate increased pain needs at ~12–18 hours  

---

## 8. Notes

### Clinical Advantages
- **Preferred first-line ERAS pathway**  
- **Lowest PONV** (<10%)  
- **Best pain control** (NRS 0–3)  
- **Motor-sparing** → safest POD 0 mobilization  
- **Lowest delirium risk** in older adults  

### Ideal Patient Population
- Opioid-naïve  
- High PONV risk  
- OSA  
- Elderly and frail (avoids opioid delirium/respiratory depression)  
- Patients desiring rapid recovery and discharge  

### Contraindications
- Patient refusal  
- Anticoagulation outside ASRA windows  
- Active infection at injection site  
- Amide local anesthetic allergy  
- OFIA contraindications:
  - Acute psychosis  
  - Severe uncontrolled HTN (SBP >180 mmHg)  
  - Advanced AV block without pacemaker  

---

## 9. References
See: **../../07_References_Evidence_2024.md**
